Close

Trending

PARP rivals close in on AZ and Merck’s market leading Lynparza

Unlocking the potential of connected commercialisation solutions

Considerations for Mobile Health Technology Developers: Part 2

Novo Nordisk achieve headline results with icodec insulin

Roche gets FDA approval for HER2 breast cancer diagnostic

Clovis

cancer-t-cells-16_9

News/ News/ Oncology

EU regulators approve AstraZeneca’s Lynparza in pancreatic cancer

Richard Staines AstraZeneca, Clovis, GlaxoSmithKline, MSD, Pfizer 0 Comment

The European Commission has approved AstraZeneca and MSD’s Lynparza (olaparib) in pancreatic cancer patients with a certain mutation. Approval in metastatic

X

EU regulators approve AstraZeneca’s Lynparza in pancreatic cancer

https://pharmaphorum.com/news/eu-regulators-approve-astrazenecas-lynparza-in-pancreatic-cancer/

Lynparza

News/ News/ Oncology/ Top stories

AZ/Merck & Co take on Clovis as FDA approves prostate cancer drug

Richard Staines AstraZeneca, cancer, Clovis, Merck & Co, Oncology, Prostate cancer 0 Comment

The FDA has approved AstraZeneca and Merck & Co’s Lynparza (olaparib) in metastatic castration-resistant prostate cancer, just days after the regulator

X

AZ/Merck & Co take on Clovis as FDA approves prostate cancer drug

https://pharmaphorum.com/news/az-merck-cos-lynparza/

clovis-oncology

News/ News/ Oncology

Clovis steals march on AZ with PARP prostate approval

Richard Staines AstraZeneca, cancer, Clovis, Prostate cancer, Rubraca 0 Comment

Shares in US-based Clovis Oncology have ticked up after the biotech became the first to get a PARP

X

Clovis steals march on AZ with PARP prostate approval

https://pharmaphorum.com/news/clovis-steals-march-on-az-with-parp-prostate-approval/

Lynparza

News/ News/ Oncology

AZ and MSD’s Lynparza gets fast prostate cancer FDA review

Richard Staines AstraZeneca, cancer, Clovis, Prostate cancer 0 Comment

The FDA has granted AstraZeneca/MSD’s PARP-targeting drug Lynparza a fast review in prostate cancer, following hot on the

X

AZ and MSD’s Lynparza gets fast prostate cancer FDA review

https://pharmaphorum.com/news/az-and-msds-lynparza-gets-fast-prostate-cancer-fda-review/

clovis-oncology

News/ News/ Oncology

Clovis takes PARP prostate cancer pole position with fast FDA review of Rubraca

Richard Staines cancer, Clovis, Prostate cancer 0 Comment

The FDA has granted a fast review for Clovis Oncology’s Rubraca PARP drug in certain patients with prostate

X

Clovis takes PARP prostate cancer pole position with fast FDA review of Rubraca

https://pharmaphorum.com/news/clovis-takes-parp-prostate-cancer-pole-position-with-fast-fda-review-of-rubraca/

clovis-oncology

News/ News/ Oncology

New price gets Clovis’ PARP inhibitor on the CDF

George Underwood CDF, Clovis, Clovis Oncology, ovarian cancer, PARP inhibitor, Rubraca 0 Comment

NICE has reversed its decision on Clovis Oncology’s PARP inhibitor Rubraca (rucaparib) and will allow the drug to

X

New price gets Clovis’ PARP inhibitor on the CDF

https://pharmaphorum.com/news/new-price-gets-clovis-parp-inhibitor-on-the-cdf/

ESMO-2019-roundup

Oncology/ Views & Analysis/ Views and analysis

ESMO 2019 roundup

Richard Staines AbbVie, Amgen, AstraZeneca, cancer, Clovis, ESMO, GSK, Merck & Co 0 Comment

The European Society for Medical Oncology (ESMO) is growing in stature, with an increasing number of oncology-focused pharma

X

ESMO 2019 roundup

https://pharmaphorum.com/views-analysis-oncology/esmo-2019-roundup/

clovis-oncology

News/ News/ Oncology

Clovis signs radiopharmaceuticals R&D deal with German biotech 3B

Richard Staines cancer, Clovis, R&D, radiopharmaceuticals 0 Comment

Clovis Oncology has become the latest pharma to invest in radiopharmaceuticals, signing a licensing and collaboration deal with

X

Clovis signs radiopharmaceuticals R&D deal with German biotech 3B

https://pharmaphorum.com/news/clovis-signs-radiopharmaceuticals-rd-deal-with-german-biotech-3b/

Cancer-cell

News/ News/ Oncology

Clovis’ Rubraca is latest PARP drug showing promise in pancreatic cancer

Richard Staines cancer, Clovis, pancreatic cancer 0 Comment

Clovis Oncology’s Rubraca has become the latest PARP drug to show potential in pancreatic cancer, as pharma companies

X

Clovis’ Rubraca is latest PARP drug showing promise in pancreatic cancer

https://pharmaphorum.com/news/clovis-rubraca/

1 2 3

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com